For the readers interested in the stock health of Takeda Pharmaceutical Company Limited (TAK). It is currently valued at $14.13. When the transactions were called off in the previous session, Stock hit the highs of $14.32, after setting-off with the price of $14.27. Company’s stock value dipped to $13.92 during the trading on the day. When the trading was stopped its value was $13.93.Recently in News on May 11, 2022, Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022. – Strong Performance Against FY2021 Management Guidance with Underlying Revenue Growth of +7.4% (Reported Revenue Growth +11.6%) and Strength Across Key Business Areas. You can read further details here
Takeda Pharmaceutical Company Limited had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $15.36 on 02/18/22, with the lowest value was $13.49 for the same time period, recorded on 01/05/22.
Takeda Pharmaceutical Company Limited (TAK) full year performance was -17.28%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Takeda Pharmaceutical Company Limited shares are logging -19.53% during the 52-week period from high price, and 7.29% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $13.17 and $17.56.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1531979 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Takeda Pharmaceutical Company Limited (TAK) recorded performance in the market was 2.20%, having the revenues showcasing -7.32% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 43.73B, as it employees total of 47099 workers.
Takeda Pharmaceutical Company Limited (TAK) in the eye of market guru’s
During the last month, 4 analysts gave the Takeda Pharmaceutical Company Limited a BUY rating, 2 of the polled analysts branded the stock as an OVERWEIGHT, 7 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 14.57, with a change in the price was noted +0.41. In a similar fashion, Takeda Pharmaceutical Company Limited posted a movement of +2.95% for the period of last 100 days, recording 2,699,830 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for TAK is recording 0.82 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.79.
Takeda Pharmaceutical Company Limited (TAK): Stocks Technical analysis and Trends
Raw Stochastic average of Takeda Pharmaceutical Company Limited in the period of last 50 days is set at 16.92%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 19.57%. In the last 20 days, the company’s Stochastic %K was 15.70% and its Stochastic %D was recorded 15.60%.
If we look into the earlier routines of Takeda Pharmaceutical Company Limited, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 2.20%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -3.67%, alongside a downfall of -17.28% for the period of the last 12 months. The shares -5.62% in the 7-day charts and went up by -5.94% in the period of the last 30 days. Common stock shares were lifted by -7.32% during last recorded quarter.